Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/16
A61K-009/14
A61K-009/20
A61K-009/22
A61K-009/24
A61P-025/04
A61K-009/50
A61K-009/48
출원번호
US-0710016
(2010-02-22)
등록번호
US-8877247
(2014-11-04)
발명자
/ 주소
Matthews, Frank
Boehm, Garth
Tang, Lijuan
Liang, Alfred
출원인 / 주소
Alpharma Pharmaceuticals LLC
대리인 / 주소
Monaco, Stephanie J.
인용정보
피인용 횟수 :
3인용 특허 :
256
초록▼
Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically sepa
Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
대표청구항▼
1. A composition comprising a plurality of multi-layer pellets comprising: a. a water-soluble core;b. an opioid antagonist comprising layer coating the core, wherein the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmefene, cyclazacine, levallorphan, salts of th
1. A composition comprising a plurality of multi-layer pellets comprising: a. a water-soluble core;b. an opioid antagonist comprising layer coating the core, wherein the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmefene, cyclazacine, levallorphan, salts of these molecules, and combinations thereof;c. a sequestering polymer layer coating the opioid antagonist comprising layer;d. an osmotic pressure regulating agent comprising layer coating the sequestering polymer layer, wherein the osmotic pressure regulating agent is selected from the group consisting of sodium chloride, sodium bromide, sodium iodide, hydroxypropyl methyl cellulose, and combinations thereof;wherein the sequestering polymer layer comprisescopolymers of acrylic and methacrylic acid esters with quaternary ammonium groups,a surfactant in an amount from 1.6% to 6.3% of the copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups on a weight-to-weight basis, andtalc in an amount of from 75% to 125% of the copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups on a weight-to-weight basis; andwherein the surfactant is selected from the group consisting of sodium lauryl sulfate, sodium docusate, dioctyl sodium sulphosuccinate, sodium lauryl sarcosinate, sodium methyl cocyl taurate, magnesium lauryl sulfate, dioctyl sodiumsulfosuceinate, sodiumdodecylbenzene sulfonate, and combinations thereof. 2. The composition of claim 1, wherein the surfactant is not comprised in the following: the water-soluble core,the opioid antagonist comprising layer,the osmotic pressure regulating agent comprising layer,the opioid agonist comprising layer, andthe controlled release layer. 3. The composition of claim 1, wherein when tested by a testing method, the composition sequesters at least 80% of the opioid antagonist as determined at 73 hours from the start of the testing method, wherein the testing method consists of first placing the composition in 500 mL of a 0.1 N HCl solution for 1 hour at 37° C. using USP paddle method, 100 rotations per minute, and then placing the composition in 500 mL of a pH 7.5, 0.05 M phosphate buffer, for 72 hours at 37° C. using USP paddle method, 100 rotations per minute, and then determining the amount of the opioid antagonist sequestered. 4. The composition of claim 1, wherein the surfactant is not comprised in the following: the water-soluble core,the opioid antagonist comprising layer,the osmotic pressure regulating agent comprising layer, andwherein when tested by a testing method, the composition sequesters at least 80% of the opioid antagonist as determined at 73 hours from the start of the testing method,wherein the testing method consists of first placing the composition in 500 mL of a 0.1 N HCI solution for 1 hour at 37° C. using USP paddle method, 100 rotations per minute, and then placing the composition in 500 mL of a pH 7.5, 0.05 M phosphate buffer, for 72 hours at 37° C. using USP paddle method, 100 rotations per minute, and then determining the amount of the opioid antagonist sequestered. 5. The composition of claim 1, wherein the osmotic pressure regulating agent comprises sodium chloride;wherein the surfactant is sodium lauryl sulfate; andwherein when tested by a testing method, the composition sequesters at least 80% of the salt of the opioid antagonist as determined at 73 hours from the start of the testing method,wherein the testing method consists of first placing the composition in 500 mL of a 0.1 N HCI solution for 1 hour at 37° C. using USP paddle method, 100 rotations per minute, and then placing the composition in 500 mL of a pH 7.5, 0.05 M phosphate buffer, for 72 hours at 37° C. using USP paddle method, 100 rotations per minute, and then determining the amount of the opioid antagonist sequestered. 6. The composition of claim 1, wherein the opioid antagonist is the salt of naltrexone;wherein the osmotic pressure regulating agent comprises sodium chloride;wherein the surfactant is sodium lauryl sulfate;wherein the opioid agonist comprising layer comprises morphine sulfate and further comprises hydroxypropyl cellulose; andwherein when tested by a testing method, the composition sequesters at least 80% of the salt of naltrexone as determined at 73 hours from the start of the testing method,wherein the testing method consists of first placing the composition in 500 mL of a 0.1 N HCI solution for 1 hour at 37° C. using USP paddle method, 100 rotations per minute, and then placing the composition in 500 mL of a pH 7.5, 0.05 M phosphate buffer, for 72 hours at 37° C. using USP paddle method, 100 rotations per minute, and then determining the amount of the salt of naltrexone sequestered. 7. The composition of claim 1, wherein the opioid antagonist is naltrexone HCI;wherein the osmotic pressure regulating agent comprises sodium chloride;wherein the surfactant is sodium lauryl sulfate; andwherein when tested by a testing method, the composition sequesters at least 80% of the naltrexone HCI as determined at 73 hours from the start of the testing method,wherein the testing method consists of first placing the composition in 500 mL of a 0.1 N HCI solution for 1 hour at 37° C. using USP paddle method, 100 rotations per minute, and then placing the composition in 500 mL of a pH 7.5, 0.05 M phosphate buffer, for 72 hours at 37° C. using USP paddle method, 100 rotations per minute, and then determining the amount of the naltrexone HCI sequestered. 8. The composition of claim 1, wherein the opioid antagonist is naltrexone HCI; andwherein the surfactant is sodium lauryl sulfate. 9. The composition of claim 1, wherein the opioid antagonist is naltrexone HCI;wherein the surfactant is sodium lauryl sulfate. andwherein the osmotic pressure regulating agent comprises sodium bromide. 10. The composition of claim 1, wherein the opioid antagonist is naltrexone HCI;wherein the surfactant is sodium lauryl sulfate; andwherein the osmotic pressure regulating agent comprises sodium iodide. 11. The composition of claim 1, wherein the opioid antagonist is naltrexone HCI;wherein the surfactant is sodium lauryl sulfate; andwherein the osmotic pressure regulating agent comprises hydroxypropyl methyl cellulose. 12. The composition of claim 1, wherein the composition does not comprise a bittering agent, a gelling agent, an irritant, or an emetic. 13. The composition of claim 1, wherein opioid antagonist is not comprised in the following: the water-soluble core,the sequestering polymer layer, andthe osmotic pressure regulating agent comprising layer. 14. A composition comprising a plurality of multi-layer pellets comprising: a. a water-soluble core;b. an opioid antagonist comprising layer coating the core, wherein the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmefene, cyclazacine, levallorphan, salts of these molecules, and combinations thereof;c. a sequestering polymer layer coating the opioid antagonist comprising layer;d. an osmotic pressure regulating agent comprising layer coating the sequestering polymer layer, wherein the osmotic pressure regulating agent is selected from the group consisting of sodium chloride, sodium bromide, sodium iodide, hydroxypropyl methyl cellulose, and combinations thereof;e. an opioid agonist comprising layer coating the osmotic pressure regulating agent comprising layer, wherein the opioid agonist is selected from the group consisting of oxycodone, a salt of oxycodone, and combinations thereof; andf. a controlled release layer coating the opioid agonist comprising layer;wherein the sequestering polymer layer comprisescopolymers of acrylic and methacrylic acid esters with quatemary ammonium groups,a surfactant in an amount from 1.6% to 6.3% of the copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups on a weight-to-weight basis, andtalc in an amount of from 75% to 125% of the copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups on a weight-to-weight basis; andwherein the surfactant is selected from the group consisting of sodium lauryl sulfate, sodium docusate, dioctyl sodium sulphosuccinate, sodium lauryl sarcosinate, sodium methyl cocyl taurate, magnesium lauryl sulfate, dioctyl sodiumsulfosuceinate, sodiumdodecylbenzene sulfonate, and combinations thereof. 15. The composition according to any of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 which further comprises an opioid agonist selected from the group consisting of morphine, oxycodone, hydrocodone, hydromorphone, dihydrocodeine, codeine, dihydromorphine, buprenorphine, salts of these molecules, and combinations thereof. 16. The composition according to claim 15 in which said agonist is morphine or a pharmaceutically acceptable salt thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (256)
Khanna Ish K. (Vernon Hills IL) Weier Richard M. (Lake Bluff IL) Collins Paul W. (Deerfield IL) Yu Yi (Skokie IL) Xu Xiangdong (Evanston IL) Partis Richard A. (Evanston IL) Koszyk Francis J. (Prospec, 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation.
Black Cameron (Pointe Claire CAX) Mancini Joseph A. (St. Leonard CAX) Lau Cheuk K. (Ile Bizard CAX) Prasit Petpiboon (Kirkland CAX) Vickers Philip J. (Pierrefonds CAX 4), 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents.
Black W. Cameron (Pointe-Claire CAX) Li Chun-Sing (Dollard Des Ormeaux CAX) Guay Daniel (Notre Dame de L\lle Perrot CAX) Prasit Petpiboon (Kirkland CAX) Roy Patrick (Dollard Des Ormeaux CAX), Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase.
Thompson Robert A. (Quaker Street NY) Brown Randy S. (Schenectady NY), Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) McGinity James (Austin TX) Bodmeier Roland (Austin TX), Aqueous dispersions of zein and preparation thereof.
Gauthier Jacques Y. (Laval CAX) Lau Cheuk K. (Ile Bizard CAX) LeBlanc Yves (Kirkland CAX) Li Chun-Sing (Dollard des Ormeaux CAX) Roy Patrick (Dollard des Ormeaux CAX) Therien Michel (Laval CAX) Wang , Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents.
Kuczynski Anthony L. ; Childers Jerry D. ; Barclay Glen E. ; Rodriguez Susan ; Merrill Sonya, Composition and dosage form comprising opioid antagonist.
Crain, Stanley M.; Shen, Ke-Fei; Sherman, Barry; Remien, Mary; Barbier, Remi; Friedmann, Nadav, Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects.
Oshlack Benjamin (New York NY) McGinity James (Austin TX) Chasin Mark (Manalapan NJ) Bodmeier Roland (Austin TX), Controlled release coatings derived from aqueous dispersions of zein.
Goldie Robert S. (Cambridge GB2) Malkowska Sandra T. A. (Cambridge GB2) Leslie Stewart T. (Cambridge GB2) Miller Ronald B. (Basel CHX), Controlled release dihydrocodeine composition.
Heafield Joanne (Cambridge GBX) Leslie Stewart I. (Cambridge GBX) Malkowska Sandra T. A. (Cambridge GBX) Neale Philip J. (Cambridge GBX), Controlled release dosage forms having a defined water content.
Miller Ronald B. (Basel CHX) Leslie Stewart T. (Cambridge GB2) Malkowska Sandra T. A. (Cambridgeshire GB2) Smith Kevin J. (Cambridge GB2) Wimmer Walter (Limburg DEX) Winkler Horst (Linter DEX) Hahn U, Controlled release formulation.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Goldie Robert S. (Comberton GB2) Malkowska Sandra T. A. (Landbeach GB2) Leslie Stewart T. (Cambridge GB2) Miller Ronald B. (Basel CHX), Controlled release hydromorphone composition.
Goldie Robert S. (Comberton GBX) Malkowska Sandra T. A. (Landbeach GBX) Leslie Stewart T. (Cambridge GBX) Miller Ronald B. (Basel CHX), Controlled release hydromorphone composition.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John Joseph (Mount Vernon NY) Kaiko Robert Francis (Weston CT), Controlled release oxycodone compositions.
Elger Gordon (Huntingdon GBX) Leslie Stewart T. (Cambridge GBX) Malkowska Sandra T. A. (Landbeach GBX) Miller Ronald B. (Basel CHX) Neale Philip J. (Harston GBX), Controlled release pharmaceutical composition.
Elger Gordon A. (Huntingdon GBX) Leslie Stewart T. (Cambridge GBX) Malkowska Sandra T. A. (Landbeach GBX) Miller Ronald B. (Basel CHX) Neale Philip J. (Cambridge GBX), Controlled release pharmaceutical composition.
Gaylord Norman G. (New Providence NJ) Schor Joseph M. (Locust Valley NY), Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surf.
Kitchell Judith P. (Newton MA) Muni Indu A. (N. Reading MA) Boyer Yvonne N. (Salem MA), Controlled, sustained release delivery system for smoking cessation.
Kitchell Judith P. (Newton MA) Muni Indu A. (N. Reading MA) Boyer Yvonne N. (Salem MA), Controlled, sustained release delivery system for treating drug dependency.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled-release formulations coated with aqueous dispersions of ethylcellulose.
Eichel ; deceased Herman J. (late of Columbus OH by Margaret A. Eichel ; executor) Massmann Brent D. (Ballwin MO) Cobb ; Jr. Joseph E. (Columbus OH), Delayed, sustained-release diltiazem pharmaceutical preparation.
Eichel ; deceased Herman J. (late of Columbus OH by Margaret A. Eichel ; executrix) Massmann Brent D. (Ballwin MO) Blazek David R. (Columbus OH), Delayed, sustained-release propranolol pharmaceutical preparation.
Prasit Petpiboon (Kirkland CAX) Guay Daniel (Iie Perrot CAX) Wang Zhaoyin (Pierrefonds CAX) Leger Serge (Dollar des Ormeaux CAX) Therien Michel (Laval CAX), Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2.
Wuest Hans-Heiner (Dossenheim DEX) Frickel Fritz-Frieder (Deidesheim DEX) Nuerrenbach Axel (Gruenstadt DEX), Diarylacetylenes and their use in treating acne.
Wright Jeri D. (Dublin CA) Barclay Brian L. (Sunnyvale CA) Swanson David R. (Palo Alto CA), Dosage forms comprising polymers comprising different molecular weights.
Feltz Dennis R. (Succasunna NJ) Kornblum Saul S. (Springfield NJ) Stoopak Samuel B. (West Caldwell NJ), Gastrointestinal protective coating formulations.
Zagon Ian S. (589 Cook Ct. Hummelstown PA 17036) McLaughlin Patricia J. (1013 Roman Knoll Ct. Harrisburg PA 17109), Growth regulation and related applications of opioid antagonists.
De Corte, Bart; De Jonge, Marc Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Paul Adriaan Jan; Kavash, Robert W.; Koymans, Lucien Maria Henricus; Kukla, Michael Joseph; Ludovici, Donald William; Van Ake, HIV replication inhibiting pyrimidines.
Brooks Dee W. (Libertyville IL) Summers James B. (Libertyville IL) Rodriques Karen E. (Grayslake IL) Maki Robert G. (Kenosha WI) Dellaria Joseph F. (Lindenhurst IL) Holms James H. (Gurnee IL) Moore J, Heteroaryl N-hydroxy amides and ureas with polar substituents as 5-lipoxygenase inhibitors.
Mayer, David J.; Price, Donald D.; Mao, Jianren; Lyle, John W., Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance.
Mayer David J. (Richmond VA) Price Donald D. (Richmond VA) Mao Jianren (Richmond VA) Lyle John W. (Belmar NJ), Inhibiting the development of tolerance to and/or dependence on an addictive substance.
Rubsamen Reid M. (Berkeley CA) Lloyd Lester J. (Orinda CA) Johansson Eric T. (Dublin CA), Lockout device for controlled release of drug from patient-activateddispenser.
Sinclair John D. (Espoo FIX), Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administer.
Baker Richard W. (Palo Alto CA) Santus Giancarlo (Milan CA ITX) Vintilla-Friedman Susan (Cupertino CA), Method and therapeutic system for smoking cessation.
Qin Bo-yi (Beijing CNX) Gong Xiong-qi (Beijing CNX) Huang Mao (Beijing CNX) Sha Li-Jun (Beijing CNX) Wang Chang Yi (Cold Spring Harbor NY), Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid.
Qin Bo-yi (Beijing CNX) Shen Ke-fei (Flushing NY) Gong Xiong-qi (Beijing CNX) Crain Stanley M. (Leonia NJ) Huang Mao (Beijing CNX) Wang Chang Yi (Cold Spring Harbor NY), Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid.
Mayer David J. (Richmond VA) Price Donald D. (Richmond VA) Mao Jianren (Richmond VA) Lyle John W. (Belmar NJ), Method for the treatment of chronic pain.
Fishman Jack (Miami FL) Arnold John (Fairway KS) Sherman Fred (Hollywood FL) Hsiao Jane (Copper City FL), Method of safely providing anesthesia or conscious sedation.
Crain Stanley M. (Leonia NJ) Shen Ke-Fei (Flushing NY), Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endoge.
Crain Stanley M. (Leonia NJ) Shen Ke-fei (Flushing NY), Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other b.
Crain Stanley M. ; Shen Ke-fei, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other b.
Crain Stanley M. (Leonia NJ) Shen Ke-fei (Flushing NY), Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other o.
Bihari Bernard (29 W. 15th St. New York NY 10011) Drury Finvola (Rochester NY), Method of treating chronic herpes virus infections using an opiate receptor antagonist.
Sackler Richard S. (Greenwich CT) Kaiko Robert F. (Weston CT) Goldenheim Paul (Wilton CT), Method of treating pain by administering 24 hour oral opioid formulations.
Sackler Richard (Greenwich CT) Goldenheim Paul (Wilton CT) Kaiko Robert (Weston CT), Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasm.
Askanazi Jeffrey (Haworth NJ) Katz David P. (Dobbs Ferry NY) Manner Tuula (Turku FIX), Methods and compositions for treating acute or chronic pain and drug addiction.
Lau Cheuk Kun (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques-Yves (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducha, N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors.
Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Belley Michel (Pierrefonds CAX), N-benzyl-3-indoleacetic acids as antiinflammatory drugs.
Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques Y. (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducharme, N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors.
Barclay Brian L. (Sunnyvale CA) Childers Jerry D. (Sunnyvale CA) Wright Jeri (Dublin CA) Place Virgil A. (Kawaihae HI) Wong Patrick S. L. (Palo Alto CA), Oral osmotic device with hydrogel driving member.
Shaw Irving F. (East Rockaway NY) Berk Jerome (New Rochelle NY), Orally administered drug composition for therapy in the treatment of narcotic drug addiction.
Wong Patrick S. L. (Hayward CA) Barclay Brian (Sunnyvale CA) Deters Joseph C. (Mt. View CA) Theeuwes Felix (Los Altos CA), Osmotic device with dual thermodynamic activity.
Guittard George V. (Cupertino CA) Deters Joseph C. (Mountain View CA) Theeuwes Felix (Los Altos CA) Cortese Richard (San Jose CA), Osmotic system with instant drug availability.
Theeuwes Felix (1634 Fallen Leaf La. Los Altos CA 94022) Yum Su Il (1021 Runnymead Ct. Los Altos CA 94022), Osmotically driven syringe with programmable agent delivery.
Guillaumet Grald (Orleans FRX) Flouzat Christine (Clermont Ferrand FRX) Devissaguet Michelle (Neuilly sur Seine FRX) Renard Pierre (Versailles FRX) Caignard Daniel H. (Paris FRX) Adam Grard (le Mesni, Oxazolopyridine compounds, compositions and use.
Rzeszotarski Waclaw J. (Millersville MD) Mavunkel Babu J. (Baltimore MD), Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists.
Rzeszotarski Waclaw J. (Millersville MD) Mavunkel Babu J. (Baltimore MD), Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists.
Steppuhn Karin G. (Berlin DEX) Bressler Karin (Berlin DEX) Gieseler Martin (Berlin DEX) Stephens David N. (Berlin DEX) Turski Lechoslaw (Berlin DEX), Pharmaceutical agent for treatment of withdrawal symptoms.
Elger Gordon A. (Huntingdon GBX) Leslie Stewart T. (Cambridge GBX) Malkowska Sandra T. A. (Cambridge GBX) Miller Ronald B. (Basel CHX) Neale Philip J. (Cambridge GBX), Pharmaceutical composition comprising analgesic and anti-inflammatory agent.
Leslie Stewart Thomas,GBX ; Knott Trevor John,GBX ; Mohammad Hasssan,GBX ; Prater Derek Allan,GBX, Pharmaceutical composition containing a fusible carrier and method for producing the same.
Ronald Brown Miller CH; Stewart Thomas Leslie GB; Sandra Therese Antoinette Malkowska GB; Derek Allan Prater GB; Trevor John Knott GB; Hassan Mohammad GB, Pharmaceutical formulation.
Malkowska Sandra T. A. (Ely GB3) Buxton Ian R. (Histon GB3) Prater Derek A. (Milton GB3) Norman Alison A. (Somersham GB3), Pharmaceutical ion exchange resin composition.
Buxton Ian R. (Cambridge GBX) Critchley Helen (Cambridge GBX) Leslie Stewart T. (Cambridge GBX) Prater Derek A. (Cambridge GBX) Miller Ronald B. (Basle CHX) Malkowska Sandra T. A. (Cambridge GBX), Pharmaceutical spheroid formulation.
Buxton Ian Richard (Cambridge GBX) Critchley Helen (Cambridge GBX) Leslie Stewart Thomas (Cambridge GBX) Prater Derek Allan (Cambridge GBX) Miller Ronald Brown (Basel CHX) Malkowska Sandra Therese An, Pharmaceutical spheroid formulation.
Conte Ubaldo,ITX ; Maggi Lauretta,ITX, Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids.
Kobsa Henry (Wilmington DE) Bucher Hermann (Aachen DEX) Onkels Eckehard (Einhausen DEX), Process for microstructuring surfaces of oriented polymeric substratesusing laser radiation.
Batt Douglas G. (Wilmington DE) Pinto Donald J. P. (Newark DE) Orwat Michael J. (Wilmington DE) Petraitis Joseph J. (Glenmoore PA) Pitts William J. (Newark DE), Prostaglandin synthase inhibitors.
Goldberg Leon I. (Chicago IL) Merz Herbert (Ingelheim am Rhein DEX) Stockhaus Klaus (Bingen DEX), Quaternary derivatives of noroxymorphone which relieve intestinal immobility.
Simon David Lew, Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics.
Knott Trevor J. (Wickford GBX) Malkowska Sandra T. A. (Cambridge GBX) Neale Philip J. (Cambridge GBX) Leslie Stewart T. (Cambridge GBX) Miller Ronald B. (Basel CHX) Prater Derek A. (Cambridge GBX), Spheroid formulation.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release formulations having acrylic polymer coating.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack Benjamin ; Pedi ; Jr. Frank ; Chasin Mark, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack, Benjamin; Chasin, Mark; Pedi, Jr., Frank, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Heafield Joanne,GBX ; Knott Trevor John,GBX ; Leslie Stewart Thomas,GBX ; Malkowska Sandra Therese Antoinette,GBX ; Miller Ronald Brown,CHX ; Prater Derek Allan,GBX ; Smith Kevin John,GBX, Sustained release compositions and a method of preparing pharmaceutical compositions.
Heafield Joanne,GB2 ; Knott Trevor John,GB2 ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Miller Ronald Brown,CHX ; Prater Derek Allan,GB2 ; Smith Kevin John,GB2, Sustained release compositions of morphine and a method of preparing pharmaceutical compositions.
Chien Yie W. (North Brunswick NJ) Chiang Chin-Chih (Piscataway NJ) Tojo Kabuji (Highland Park NJ), Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration.
Gale Robert M. (Los Altos CA) Goetz Victor (Palo Alto CA) Lee Eun S. (Redwood City CA) Taskovich Lina T. (Palo Alto CA) Yum Su I. (Los Altos CA), Transdermal administration of fentanyl and device therefor.
Chen Yu-Ling (Cupertino CA) Chun Leslie L. (Palo Alto CA) Enscore David J. (Sunnyvale CA), Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine.
Crain Stanley M. (Leonia NJ) Shen Ke-fei (Flushing NY) Kessler John A. (New Canaan CT) Apfel Stuart C. (West Hempstead NY), Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.